Selected article for: "PEDV challenge and present study"
Author: Liu, Xinsheng; Zhao, Donghong; Zhou, Peng; Zhang, Yongguang; Wang, Yonglu
Title: Evaluation of the Efficacy of a Recombinant Adenovirus Expressing the Spike Protein of Porcine Epidemic Diarrhea Virus in Pigs
  • Document date: 2019_10_8
    • ID: 1lxd2457_38
    Snippet: In conclusion, the present study showed that the PEDV S protein derived from emerging PEDV variants could be inserted into an adenovirus vector and successfully expressed in vitro. Further animal studies showed that rAd-PEDV-S could induce a high humoral immune response and confer partial protection for pigs against the highly virulent PEDV challenge......
    Document: In conclusion, the present study showed that the PEDV S protein derived from emerging PEDV variants could be inserted into an adenovirus vector and successfully expressed in vitro. Further animal studies showed that rAd-PEDV-S could induce a high humoral immune response and confer partial protection for pigs against the highly virulent PEDV challenge.

    Search related documents:
    Co phrase search for related documents
    • adenovirus vector and highly virulent PEDV challenge: 1, 2
    • adenovirus vector and humoral immune response: 1, 2, 3, 4
    • adenovirus vector and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • adenovirus vector and partial protection: 1, 2, 3, 4
    • adenovirus vector and PEDV challenge: 1, 2
    • adenovirus vector and present study: 1, 2, 3, 4, 5, 6
    • animal study and humoral immune response: 1
    • animal study and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • animal study and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high humoral immune response and humoral immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • high humoral immune response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • high humoral immune response and present study: 1, 2, 3
    • highly virulent PEDV challenge and humoral immune response: 1
    • highly virulent PEDV challenge and immune response: 1, 2, 3
    • highly virulent PEDV challenge and partial protection: 1, 2, 3
    • highly virulent PEDV challenge and PEDV challenge: 1, 2, 3, 4, 5, 6, 7
    • highly virulent PEDV challenge and PEDV variant: 1
    • highly virulent PEDV challenge and present study: 1
    • humoral immune response and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24